

31. Crystalline paroxetine methanesulfonate having the following IR peaks: 531, 546, 777, 838, 931, 962, 1038, 1100, 1169, 1208, 1469, 1500, 1515, 1615, 2577, 2869, 2900, 3023.

32. Crystalline paroxetine methanesulfonate.

33. A pharmaceutical composition comprising crystalline paroxetine methanesulfonate admixed with a pharmaceutically acceptable carrier or diluent, wherein the crystalline paroxetine methanesulfonate has been crystallized from ethyl acetate.

34. A pharmaceutical composition comprising crystalline paroxetine methanesulfonate admixed with a pharmaceutically acceptable carrier or diluent, wherein the crystalline paroxetine methanesulfonate has the following IR peaks: 531, 546, 777, 838, 931, 962, 1038, 1100, 1169, 1208, 1469, 1500, 1515, 1615, 2577, 2869, 2900, 3023.

35. A pharmaceutical composition comprising crystalline paroxetine methanesulfonate admixed with a pharmaceutically acceptable carrier or diluent.

36. A method for treating a patient suffering from a condition selected from the group consisting of depression, obsessive compulsive disorders, panic disorders, bulimia, anorexia, pain, obesity, senile dementia, migraine, and social phobias, comprising administering to the patient a pharmaceutical composition comprising crystalline paroxetine

methanesulfonate admixed with a pharmaceutically acceptable carrier or diluent, wherein the crystalline paroxetine methanesulfonate has been crystallized from ethyl acetate.

37. A method for treating a patient suffering from a condition selected from the group consisting of depression, obsessive compulsive disorders, panic disorders, bulimia, anorexia, pain, obesity, senile dementia, migraine, and social phobias, comprising administering to the patient a pharmaceutical composition comprising crystalline paroxetine methanesulfonate admixed with a pharmaceutically acceptable carrier or diluent, wherein the crystalline paroxetine methanesulfonate has the following IR peaks: 531, 546, 777, 838, 931, 962, 1038, 1100, 1169, 1208, 1469, 1500, 1515, 1615, 2577, 2869, 2900, 3023.

38. A method for treating a patient suffering from a condition selected from the group consisting of depression, obsessive compulsive disorders, panic disorders, bulimia, anorexia, pain, obesity, senile dementia, migraine, and social phobias, comprising administering to the patient a pharmaceutical composition comprising crystalline paroxetine methanesulfonate admixed with a pharmaceutically acceptable carrier or diluent.

39. A process for preparing paroxetine hydrochloride comprising contacting paroxetine methanesulfonate and hydrochloric acid and thereby forming paroxetine hydrochloride.